HCM
KPTI icon

Highbridge Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Highbridge Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,753
Closed -$547K – 1657
2015
Q4 		$547K Sell
2,753
-740
-21% -$160K 0.01% 964
2015
Q3 		$551K Buy
3,493
+2,513
+256% +$672K 0.01% 993
2015
Q2 		$400K Buy
+980
New +$424K 0.01% 1044

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Highbridge Capital Management's KPTI Position: Q1 2017 in Review

Highbridge Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2017, closing a stake of 2,664 shares — an estimated $376K sold.

Highbridge Capital Management first reported a position in KPTI in Q3 2015 and held it in 5 quarters. The position peaked at $470K in Q4 2015. 80 funds tracked by Wall St. Rank hold KPTI as of Q1 2017.

  • Highbridge Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 2,664 Karyopharm Therapeutics shares in Q1 2017, an estimated $376K.
  • Highbridge Capital Management first reported a position in Karyopharm Therapeutics in Q3 2015 and held it in 5 quarters.
  • Highbridge Capital Management's Karyopharm Therapeutics position peaked at $470K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.